YOLFTbeta
Palisade Bio Inc

Palisade Bio Inc

PALI · NASDAQ · Healthcare / Biotechnology

1.12USD-0.02 (-1.75%)

Price History

Full chart

Market Stats

Previous Close1.14
Open1.15
Day Range1.08 – 1.15
52-Week Range0.96 – 2.86
Volume1.46M
Market Cap252.69M
P/E (TTM)2.23
Forward P/E0.00
EPS0.65
Dividend Yield0.00%
Beta1.55
50-Day Avg1.98
200-Day Avg1.93

About

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. J. D. Finley
  • Employees14
  • Headquarters4600 South Syracuse Street, Denver, CO, United States, 80237, USA
  • Websitehttps://www.palisadebio.com

Leadership

  • Mr. J. D. FinleyCEO, CFO & Director · b. 1958
  • Dr. Mitchell Lawrence Jones M.D., Ph.D.President & Chief Medical Officer · b. 1977
  • Dr. Joerg Heyer Ph.D.Head of Translational Science & Medicine
  • Dr. James Izanec M.D.VP & Head of Clinical Development
  • Mr. Daniel J. LarkinsHead of Global Regulatory Affairs
  • Mr. Adarsh Patel M.B.A., M.S.Head of Chemistry, Manufacturing & Controls
  • Ms. Dawn LouroVP & Head of Clinical Operations
  • Mr. Ryker WillieSenior VP of Finance & Corporate Controller

Financials

Income Statement

Currency: USD2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue309.14K265.76K306.06K--733.44K390.63K407.71K110.00K18.83K10.42K16.25K260.00K260.00K15.39K13.52K0250.00K250.00K00
Growth (%)--14.03%+15.16%----46.74%+4.37%-73.02%-82.88%-44.69%+55.96%+1500.39%0.00%-94.08%-12.17%-100.00%-0.00%-100.00%-
Cost of Revenue53.58K53.58K-65.76K----------990.00K-146.00K168.00K167.00K4.00K3.00K3.00K
Gross Profit255.57K265.76K306.06K--733.44K390.63K407.71K110.00K18.83K10.42K16.25K260.00K1.25M15.39K-146.00K-168.00K-167.00K250.00K-3.00K-3.00K
Gross Margin82.67%100.00%100.00%--100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%480.77%100.00%-1079.88%--66.80%100.00%--
Operating Expense1.82M3.43M6.67M--15.92M13.38M10.56M12.63M17.45M19.17M20.18M13.47M9.51M8.65M9.15M41.69M15.55M13.32M14.86M18.05M
Operating Income-1.57M-3.16M-6.37M-11.83M-10.47M-15.19M-12.99M-10.16M-12.52M-17.44M-19.16M-20.17M-13.21M-8.26M-8.63M-9.30M-41.85M-15.72M-13.07M-14.86M-18.06M
Operating Margin-506.89%-1189.80%-2080.66%---2070.39%-3325.44%-2491.00%-11385.45%-92582.17%-183901.32%-124135.17%-5082.69%-3176.54%-56073.79%-68764.79%--6288.40%-5228.00%--
EBITDA-1.50M-3.08M-6.13M-11.77M-10.27M-18.25M-12.33M-9.91M-18.19M-20.66M-18.74M-19.60M-15.22M-4.73M-8.20M-9.94M-24.22M-14.24M-12.28M-14.42M-16.77M
EBITDA Margin-483.60%-1160.45%-2003.88%---2488.83%-3156.74%-2430.17%-16539.09%-109695.75%-179917.44%-120620.46%-5853.08%-1819.62%-53261.01%-73528.11%--5697.60%-4912.40%--
Net Income-1.65M-3.15M-7.06M-11.83M-10.36M-18.39M-12.52M-10.12M-19.83M-22.63M-20.90M-21.07M-15.67M-4.92M-8.35M-10.32M-26.62M-14.26M-12.30M-14.44M-16.78M
Net Income Margin-534.38%-1184.16%-2307.74%---2506.96%-3204.86%-2482.66%-18029.09%-120156.11%-200671.98%-129724.24%-6025.38%-1894.23%-54254.90%-76346.15%--5704.00%-4920.00%--
R&D568.30K1.66M3.44M6.51M5.35M9.16M7.36M6.11M7.13M8.13M12.64M12.84M8.00M3.96M4.06M3.10M2.43M6.55M6.89M9.06M10.19M
R&D as % of Total Revenue183.83%624.63%1123.97%--1249.46%1882.88%1497.64%6485.45%43195.45%121311.32%79059.46%3078.46%1523.08%26380.41%22921.60%-2618.80%2757.20%--
Interest Expense102.77K9.46K007762.66K8212.70K1.39M1.62M1.82M1.14M159.07K7.70K8.92K235.00K2.40M13.00K15.00K12.00K10.00K
Interest Expense % of Total Revenue33.24%3.56%0.00%--0.36%0.21%0.66%1267.27%8607.23%17433.04%7023.27%61.18%2.96%57.94%1738.17%-5.20%6.00%--

Balance Sheet

Currency: USD2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets569.85K1.93M7.83M5.47M3.01M10.59M4.09M8.75M19.41M29.84M14.95M22.60M13.88M7.68M6.58M3.02M12.51M15.76M14.05M10.88M134.34M
Total Liabilities1.03M380.36K1.02M1.27M8.02M2.74M2.43M1.78M11.00M12.12M9.98M11.27M5.37M1.63M1.46M10.12M5.15M3.28M2.74M3.39M4.96M
Total Equity-460.17K1.55M6.81M4.20M-5.02M7.85M1.66M6.97M8.42M17.72M4.97M11.33M8.52M6.05M5.13M-7.10M7.37M12.48M11.31M7.49M129.38M
Cash526.38K1.81M7.40M4.90M2.31M9.26M2.35M7.44M16.85M12.52M4.72M15.19M6.67M5.79M5.11M713.00K10.49M12.38M12.43M9.82M133.38M
Total Debt153.60K28.39K------7.70M8.79M7.93M3.71M-5.04M288.54K1.42M199.00K404.00K369.00K169.00K71.00K
Net Debt-372.79K-1.78M-7.40M-4.90M-2.31M-9.26M-2.35M-7.44M-9.15M-3.73M3.21M-11.49M-6.67M-749.11K-4.83M708.00K-10.30M-11.98M-12.06M-9.65M-133.31M

Cash Flow

Currency: USD2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-728.59K-3.33M-4.00M-6.86M-5.14M-9.98M-8.10M-8.48M-10.59M-11.71M-18.93M-15.62M-13.42M-7.69M-7.26M-4.77M-14.77M-13.36M-11.13M-12.19M-10.85M
Investing Cash Flow-18.34K-59.21K-229.63K-193.63K--332.68K-480.85K-254.86K-537.05K-15.56M7.25M2.36M-94.05K5.00M3.92M-6.00K-54.00K-10.00K-4.00K--
Financing Cash Flow1.23M4.67M9.83M4.55M2.76M17.27M1.67M13.82M20.52M22.94M3.89M23.74M4.99M1.81M6.59M1.89M24.61M15.26M11.19M9.58M134.44M
Capital Expenditure18.34K59.21K229.63K193.63K210.78K332.68K480.85K254.86K537.05K556.35K243.58K161.11K94.05K1.71K6.00K6.00K010.00K4.00K00
Free Cash Flow-746.93K-3.39M-4.23M-7.05M-5.36M-10.31M-8.58M-8.73M-11.13M-12.26M-19.18M-15.78M-13.51M-7.69M-7.26M-4.77M-14.77M-13.37M-11.14M-12.19M-10.85M
Dividends Paid----------------99.00K----
FCF to OCF102.52%101.78%105.74%102.82%104.10%103.33%105.94%103.01%105.07%104.75%101.29%101.03%100.70%100.02%100.00%100.13%100.00%100.07%100.04%100.00%100.00%
Dividend Paid to FCF-----------------0.67%----

Earnings

Report DateDec 31, 2006Mar 31, 2007Jun 30, 2007Nov 14, 2007Feb 27, 2008May 15, 2008Aug 15, 2008Nov 14, 2008May 18, 2009Aug 14, 2009Nov 17, 2009May 18, 2010Aug 17, 2010Nov 16, 2010Mar 16, 2011May 10, 2011Aug 10, 2011Nov 9, 2011Mar 29, 2012May 9, 2012Aug 10, 2012Nov 9, 2012Mar 15, 2013May 10, 2013Aug 9, 2013Nov 12, 2013Mar 10, 2014May 12, 2014Aug 8, 2014Nov 7, 2014Mar 16, 2015May 8, 2015Aug 10, 2015Nov 9, 2015Mar 14, 2016May 9, 2016Aug 11, 2016Nov 8, 2016Mar 23, 2017May 10, 2017Aug 8, 2017Nov 8, 2017Mar 22, 2018Apr 2, 2018Aug 15, 2018Nov 14, 2018Mar 22, 2019May 14, 2019Aug 14, 2019Nov 14, 2019Mar 27, 2020May 15, 2020Aug 13, 2020Nov 10, 2020Mar 22, 2021May 14, 2021Aug 23, 2021Nov 12, 2021Mar 17, 2022May 13, 2022Aug 15, 2022Nov 14, 2022Mar 22, 2023May 11, 2023Aug 10, 2023Nov 9, 2023Mar 26, 2024May 13, 2024Aug 12, 2024Nov 12, 2024Mar 25, 2025May 12, 2025Aug 11, 2025Nov 10, 2025Mar 25, 2026May 13, 2026Aug 10, 2026Nov 9, 2026
EPS Estimate--------------28.60-26.00-26.00-28.60-18.20-15.60--13.00-10.40-15.60-11.70-11.70-10.40-15.60-15.60-13.00-14.30-13.00-15.60-16.47-16.90-5070.00-4290.00-3900.00-2730.00-3120.00-3120.00-4380.00-0.00---------------270.00-180.00-14.00-217.50-67.50-2.43-9.90-6.82-6.15-5.17-3.75-2.93-3.35-1.99-0.81-0.56-0.27-0.03-0.04-0.05-0.06
EPS Actual-61217.34-41775.07-72516.70-56642.81-105299.98-83780.50-107769.91-115647.2729729.21-110534.44-172542.50-205435.99-136466.94-23.40-13.00-18.20-20.80-18.20-13.00-55795.73-7.80-10.40-7.80-10.40-23.40-23.40-10.40-18.20-20.80-13.00-15.60-15.60-15.60-15.60-3900.00-5460.00-3120.00-3900.00-4200.00-2580.00-2160.00-0.18-0.18-2.80-0.80-0.12-0.22-0.22-4.39-4.39-4.39-4.39-4.39-4.39-0.25-4.39-3.53-187.27-165.75-13.00-90.00-61.066.47-8.10-7.95-7.35-6.45-4.59-3.32-2.32-0.69-0.47-0.58-0.38-0.06-0.05-0.05-
Surprise-------------18.18%50.00%30.00%27.27%0.00%16.67%-40.00%0.00%50.00%11.11%-100.00%-125.00%33.33%-16.67%-60.00%9.09%-20.00%0.00%5.28%7.69%23.08%-27.27%20.00%-42.86%-34.62%17.31%50.68%----------------30.64%7.92%7.14%58.62%9.54%366.26%18.18%-16.57%-19.51%-24.76%-22.40%-13.31%30.75%65.27%41.98%-3.57%-40.74%-97.17%-14.50%0.00%-
Timing----------------------------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market-Pre-market-----After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hours--After-hours-

Key Statistics & Ratios

Market Cap252.69M
Enterprise Value148.46M
Trailing P/E2.23
Forward P/E0.00
Price / Sales505.38
Price / Book2.31
EPS0.65
Book Value0.701
Revenue (TTM)500.00K
Gross Profit (TTM)500.00K
EBITDA-35.35M
Profit Margin0.00%
Operating Margin-2339.60%
Return on Equity-51.37%
Return on Assets-32.98%
Shares Outstanding174.27M
Shares Float138.85M
Beta1.55
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 3 analystsTarget 10.22
  • Strong Buy
    2
  • Buy
    1

Ownership Breakdown

Institutions
101.13%
Insiders
2.15%
Retail / Other
0.00%

Top Institutional Holders

  • Soleus Capital Management, L.P.
    13.06M7.50%
  • Ameriprise Financial Inc
    11.51M6.60%
  • B Group, Inc
    11.41M6.55%
  • HHG PLC
    10.69M6.13%
  • Octagon Capital Advisors LP
    10.28M5.90%
  • Perceptive Advisors LLC
    8.43M4.83%
  • COMMODORE CAPITAL LP
    7.18M4.12%
  • RA Capital Management, LLC
    7.12M4.09%
  • Franklin Templeton Inc
    5.79M3.32%
  • The Goldman Sachs Group Inc
    5.37M3.08%
  • Boxer Capital Management, LLC
    4.80M2.75%
  • Morgan Stanley - Brokerage Accounts
    4.55M2.61%
  • Adage Capital Partners Gp LLC
    4.50M2.58%
  • Eversept Partners, LP
    4.18M2.40%
  • Wellington Management Company LLP
    3.70M2.13%
  • Balyasny Asset Management LLC
    3.27M1.88%
  • Federated Hermes Inc
    3.14M1.80%

Top Fund Holders

  • Franklin Biotechnology Discv A(acc)USD
    3.95M2.27%
  • iShares Russell 2000 ETF
    3.67M2.11%
  • Federated Hermes Kaufmann Small Cap A
    3.14M1.80%

Stock Splits

  • Apr 8, 20241:15
  • Nov 16, 20221:50
  • Apr 28, 20211:6
  • Jul 18, 20191:20
  • Jan 9, 20171:13